Alpha-1 antitrypsin deficiency

Last updated

Alpha-1 antitrypsin deficiency
Other namesα1-antitrypsin deficiency
A1AT.png
Structure of Alpha-1 antitrypsin
Specialty Pulmonology, Hepatology, Medical genetics
Symptoms Shortness of breath, wheezing, yellowish skin [1]
Complications COPD, cirrhosis, neonatal jaundice, panniculitis [1]
Usual onset20 to 50 years old [1]
CausesMutation in the SERPINA1 gene [1]
Risk factors Northern European and Iberian ancestry
Diagnostic method Based on symptoms, blood tests, genetic tests [2]
Differential diagnosis Asthma [1]
TreatmentMedications, lung transplant, liver transplant [2]
Medication Bronchodilators, inhaled steroids, antibiotics, intravenous infusions of A1AT protein [2]
Prognosis Life expectancy ~50 years (smokers), nearly normal (non-smokers) [3]
Frequency1 in 2,500 (Europeans) [1]

Alpha-1 antitrypsin deficiency (A1AD or AATD) is a genetic disorder that may result in lung disease or liver disease. [1] Onset of lung problems is typically between 20 and 50 years of age. [1] This may result in shortness of breath, wheezing, or an increased risk of lung infections. [1] [2] Complications may include chronic obstructive pulmonary disease (COPD), cirrhosis, neonatal jaundice, or panniculitis. [1]

Contents

A1AD is due to a mutation in the SERPINA1 gene that results in not enough alpha-1 antitrypsin (A1AT). [1] Risk factors for lung disease include tobacco smoking and environmental dust. [1] The underlying mechanism involves unblocked neutrophil elastase and buildup of abnormal A1AT in the liver. [1] It is autosomal co-dominant, meaning that one defective allele tends to result in milder disease than two defective alleles. [1] The diagnosis is suspected based on symptoms and confirmed by blood tests or genetic tests. [2]

Treatment of lung disease may include bronchodilators, inhaled steroids, and, when infections occur, antibiotics. [2] Intravenous infusions of the A1AT protein or in severe disease lung transplantation may also be recommended. [2] In those with severe liver disease liver transplantation may be an option. [2] [4] Avoiding smoking is recommended. [2] Vaccination for influenza, pneumococcus, and hepatitis is also recommended. [2] Life expectancy among those who smoke is 50 years while among those who do not smoke it is almost normal. [3]

The condition affects about 1 in 2,500 people of European descent. [1] Severe deficiency occurs in about 1 in 5,000. [5] In Asians it is uncommon. [1] About 3% of people with COPD are believed to have the condition. [5] Alpha-1 antitrypsin deficiency was first described in the 1960s. [6]

Signs and symptoms

Individuals with A1AD may develop emphysema, [1] or chronic obstructive pulmonary disease during their thirties or forties even without a history of smoking, though smoking greatly increases the risk. [7] Symptoms may include shortness of breath (on exertion and later at rest), wheezing, and sputum production. Symptoms may resemble recurrent respiratory infections or asthma. [8]

A1AD may cause several manifestations associated with liver disease, which include impaired liver function and cirrhosis. In newborns, alpha-1 antitrypsin deficiency can result in early onset jaundice followed by prolonged jaundice. Between 3% and 5% of children with ZZ mutations develop life-threatening liver disease, including liver failure. [9] A1AD is a leading reason for liver transplantation in newborns. [9] In newborns and children, A1AD may cause jaundice, poor feeding, poor weight gain, hepatomegaly and splenomegaly. [9]

Conditions associated with alpha-1 antitrypsin deficiency, occurring due to paucity of AAT in circulation allowing uninhibited inflammation in lungs, and accumulation of mutated AAT in the liver Conditions associated with Alpha-1 Antitrypsin Deficiency.png
Conditions associated with alpha-1 antitrypsin deficiency, occurring due to paucity of AAT in circulation allowing uninhibited inflammation in lungs, and accumulation of mutated AAT in the liver

Apart from COPD and chronic liver disease, α1-antitrypsin deficiency has been associated with necrotizing panniculitis (a skin condition) and with granulomatosis with polyangiitis in which inflammation of the blood vessels may affect a number of organs but predominantly the lungs and the kidneys. [10]

Genetics

Serpin peptidase inhibitor, clade A, member 1 (SERPINA1) is the gene that encodes the protein alpha-1 antitrypsin. SERPINA1 has been localized to chromosome 14q32. Over 75 mutations of the SERPINA1 gene have been identified, many with clinically significant effects. [11] The most common cause of severe deficiency, PiZ, is a single base-pair substitution leading to a glutamic acid to lysine mutation at position 342 (dbSNP: rs28929474), while PiS is caused by a glutamic acid to valine mutation at position 264 (dbSNP: rs17580). Other rarer forms have been described [ citation needed ].

Pathophysiology

Photomicrograph of a liver biopsy from a patient with alpha-1 antitrypsin deficiency. The PAS with diastase stain shows the diastase-resistant pink globules that are characteristic of this disease. Alpha-1 antitrypsin deficiency.PAS Diastase.jpg
Photomicrograph of a liver biopsy from a patient with alpha-1 antitrypsin deficiency. The PAS with diastase stain shows the diastase-resistant pink globules that are characteristic of this disease.

A1AT is a glycoprotein mainly produced in the liver by hepatocytes, [9] and, in some quantity, by enterocytes, monocytes, and macrophages. [12] In a healthy lung, it functions as an inhibitor against neutrophil elastase, [13] a neutral serine protease that controls lung elastolytic activity which stimulates mucus secretion and CXCL8 release from epithelial cells that perpetuate the inflammatory state. [14] With A1AT deficiency, neutrophil elastase can disrupt elastin and components of the alveolar wall of the lung that may lead to emphysema, and hypersecretion of mucus that can develop into chronic bronchitis. [15] Both conditions are the makeup of chronic obstructive pulmonary disease (COPD). [16]

Normal blood levels of alpha-1 antitrypsin may vary with analytical method but are typically around 1.0-2.7 g/L. [17] In individuals with PiSS, PiMZ and PiSZ genotypes, blood levels of A1AT are reduced to between 40 and 60% of normal levels; this is usually sufficient to protect the lungs from the effects of elastase in people who do not smoke. However, in individuals with the PiZZ genotype, A1AT levels are less than 15% of normal, and they are likely to develop panlobular emphysema at a young age. Cigarette smoke is especially harmful to individuals with A1AD. [7] In addition to increasing the inflammatory reaction in the airways, cigarette smoke directly inactivates alpha-1 antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a factor of 2,000.[ citation needed ]

With A1AT deficiency, the pathogenesis of the lung disease is different from that of the liver disease, which is caused by the accumulation of abnormal A1AT proteins in the liver, resulting in liver damage. [9] As such, lung disease and liver disease of A1AT deficiency appear unrelated, and the presence of one does not appear to predict the presence of the other. [9] Between 10 and 15% of people with the PiZZ genotype will develop liver fibrosis or liver cirrhosis, because the A1AT is not secreted properly and therefore accumulates in the liver. [18] The mutant Z form of A1AT protein undergoes inefficient protein folding (a physical process where a protein chain achieves its final conformation). 85 percent of the mutant Z form are unable to be secreted and remain in the hepatocyte. [9] Nearly all liver disease caused by A1AT is due to the PiZZ genotype, although other genotypes involving different combinations of mutated alleles (compound heterozygotes) may also result in liver disease. [9] A liver biopsy in such cases will reveal PAS-positive, diastase-resistant inclusions within hepatocytes. [9] Unlike glycogen and other mucins which are diastase sensitive (i.e., diastase treatment disables PAS staining), A1AT deficient hepatocytes will stain with PAS even after diastase treatment - a state thus referred to as "diastase resistant".[ citation needed ] The accumulation of these inclusions or globules is the main cause of liver injury in A1AT deficiency. However, not all individuals with PiZZ genotype develop liver disease (incomplete penetrance), despite the presence of accumulated mutated protein in the liver. [9] Therefore, additional factors (environmental, genetic, etc.) likely influence whether liver disease develops. [9]

Diagnosis

Emphysema due to alpha-1 antitrypsin deficiency Anti1Tripsine.PNG
Emphysema due to alpha-1 antitrypsin deficiency
Computed tomography of the lung showing emphysema and bullae in the lower lobes of a subject with type ZZ alpha-1 antitrypsin deficiency. There is also increased lung density in areas with compression of lung tissue by the bullae. Alpha 1-antitrypsine deficiency lung CT scan.JPEG
Computed tomography of the lung showing emphysema and bullae in the lower lobes of a subject with type ZZ alpha-1 antitrypsin deficiency. There is also increased lung density in areas with compression of lung tissue by the bullae.

The gold standard of diagnosis for A1AD consists of blood tests to determine the phenotype of the AAT protein or genotype analysis of DNA. [9] Liver biopsy is the gold standard for determining the extent of hepatic fibrosis and assessing for the presence of cirrhosis. [9]

A1AT deficiency remains undiagnosed in many patients. Patients are usually labeled as having COPD without an underlying cause. It is estimated that about 1% of all COPD patients actually have an A1AT deficiency. Testing is recommended in those with COPD, unexplained liver disease, unexplained bronchiectasis, granulomatosis with polyangiitis or necrotizing panniculitis. [10] American guidelines recommend that all people with COPD are tested, [10] whereas British guidelines recommend this only in people who develop COPD at a young age with a limited smoking history or with a family history. [19] The initial test performed is serum A1AT level. A low level of A1AT confirms the diagnosis and further assessment with A1AT protein phenotyping and A1AT genotyping should be carried out subsequently. [11]

As protein electrophoresis does not completely distinguish between A1AT and other minor proteins at the alpha-1 position (agarose gel), antitrypsin can be more directly and specifically measured using a nephelometric or immunoturbidimetric method. Thus, protein electrophoresis is useful for screening and identifying individuals likely to have a deficiency. A1AT is further analyzed by isoelectric focusing (IEF) in the pH range 4.5-5.5, where the protein migrates in a gel according to its isoelectric point or charge in a pH gradient. Normal A1AT is termed M, as it migrates toward the center of such an IEF gel. Other variants are less functional and are termed A-L and N-Z, dependent on whether they run proximal or distal to the M band. The presence of deviant bands on IEF can signify the presence of alpha-1 antitrypsin deficiency. Since the number of identified mutations has exceeded the number of letters in the alphabet, subscripts have been added to most recent discoveries in this area, as in the Pittsburgh mutation described above. As every person has two copies of the A1AT gene, a heterozygote with two different copies of the gene may have two different bands showing on electrofocusing, although a heterozygote with one null mutant that abolishes expression of the gene will only show one band. In blood test results, the IEF results are notated as, e.g., PiMM, where Pi stands for protease inhibitor and "MM" is the banding pattern of that person.[ citation needed ]

Other detection methods include use of enzyme-linked-immuno-sorbent-assays in vitro and radial immunodiffusion. Alpha-1 antitrypsin levels in the blood depend on the genotype. Some mutant forms fail to fold properly and are, thus, targeted for destruction in the proteasome, whereas others have a tendency to polymerize, thereafter being retained in the endoplasmic reticulum. The serum levels of some of the common genotypes are:[ citation needed ]

Treatment

Treatment of lung disease may include bronchodilators, inhaled steroids, and, when infections occur, antibiotics. [2] Intravenous infusions of the A1AT protein or in severe disease lung transplantation may also be recommended. [2] In those with severe liver disease liver transplantation may be an option. [2] Avoiding smoking and getting vaccinated for influenza, pneumococcus, and hepatitis is also recommended. [2]

People with lung disease due to A1AD may receive intravenous infusions of alpha-1 antitrypsin, derived from donated human plasma. This augmentation therapy is thought to arrest the course of the disease and halt any further damage to the lungs. Long-term studies of the effectiveness of A1AT replacement therapy are not available. [20] It is currently recommended that patients begin augmentation therapy only after the onset of emphysema symptoms. [11] As of 2015 there were four IV augmentation therapy manufacturers in the United States, Canada, and several European countries. IV therapies are the standard mode of augmentation therapy delivery.[ citation needed ]

Liver disease due to A1AD does not include any specific treatment, beyond routine care for chronic liver disease. [9] However, the presence of cirrhosis affects treatment is several ways. Individuals with cirrhosis and portal hypertension should avoid contact sports to minimize the risk of splenic injury. [9] All people with A1AD and cirrhosis should be screened for esophageal varices, and should avoid all alcohol consumption. [9] Nonsteroidal antiinflammatory drugs (NSAIDs) should also be avoided, as these medications may worsen liver disease in general, and may particularly accelerate the liver injury associated with A1AD. [9] Augmentation therapy is not appropriate for people with liver disease. If progressive liver failure or decompensated cirrhosis develop, then liver transplantation may be necessary. [9]

Epidemiology

Distribution of PiZZ in Europe PiZZ Europe.png
Distribution of PiZZ in Europe

People of Northern European and Iberian ancestry are at the highest risk for A1AD. Four percent of them carry the PiZ allele; between 1 in 625 and 1 in 2000 are homozygous.[ citation needed ]

Another study detected a frequency of 1 in 1550 individuals. [21] The highest prevalence of the PiZZ variant was recorded in the northern and western European countries with mean gene frequency of 0.0140. [21] Worldwide, an estimated 1.1 million people have A1AT deficiency and roughly 116 million are carriers of mutations. [21]

A1AD is one of the most common genetic diseases worldwide and the second most common metabolic disease affecting the liver. [22]

History

A1AD was discovered in 1963 by Carl-Bertil Laurell at the University of Lund in Sweden. [23] Laurell, along with a medical resident, Sten Eriksson, made the discovery after noting the absence of the α1 band on protein electrophoresis in five of 1500 samples; three of the five patients were found to have developed emphysema at a young age.[ citation needed ]

The link with liver disease was made six years later, when Harvey Sharp et al. described A1AD in the context of liver disease. [24]

Research

Recombinant and inhaled forms of A1AT treatment are being studied. [25]

Related Research Articles

<span class="mw-page-title-main">Serum protein electrophoresis</span> Laboratory test

Serum protein electrophoresis is a laboratory test that examines specific proteins in the blood called globulins. The most common indications for a serum protein electrophoresis test are to diagnose or monitor multiple myeloma, a monoclonal gammopathy of uncertain significance (MGUS), or further investigate a discrepancy between a low albumin and a relatively high total protein. Unexplained bone pain, anemia, proteinuria, chronic kidney disease, and hypercalcemia are also signs of multiple myeloma, and indications for SPE. Blood must first be collected, usually into an airtight vial or syringe. Electrophoresis is a laboratory technique in which the blood serum is applied to either an acetate membrane soaked in a liquid buffer, or to a buffered agarose gel matrix, or into liquid in a capillary tube, and exposed to an electric current to separate the serum protein components into five major fractions by size and electrical charge: serum albumin, alpha-1 globulins, alpha-2 globulins, beta 1 and 2 globulins, and gamma globulins.

<span class="mw-page-title-main">Bronchiectasis</span> Disease of the lungs

Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung. Symptoms typically include a chronic cough with mucus production. Other symptoms include shortness of breath, coughing up blood, and chest pain. Wheezing and nail clubbing may also occur. Those with the disease often get lung infections.

<span class="mw-page-title-main">Alpha-1 antitrypsin</span> Mammalian protein found in Homo sapiens

Alpha-1 antitrypsin or α1-antitrypsin is a protein belonging to the serpin superfamily. It is encoded in humans by the SERPINA1 gene. A protease inhibitor, it is also known as alpha1–proteinase inhibitor (A1PI) or alpha1-antiproteinase (A1AP) because it inhibits various proteases. In older biomedical literature it was sometimes called serum trypsin inhibitor, because its capability as a trypsin inhibitor was a salient feature of its early study. As a type of enzyme inhibitor, it protects tissues from enzymes of inflammatory cells, especially neutrophil elastase, and has a reference range in blood of 0.9–2.3 g/L, but the concentration can rise manyfold upon acute inflammation.

<span class="mw-page-title-main">Nail clubbing</span> Deformity of the finger or toe nails associated with a number of diseases

Nail clubbing, also known as digital clubbing or clubbing, is a deformity of the finger or toe nails associated with a number of diseases, mostly of the heart and lungs. When it occurs together with joint effusions, joint pains, and abnormal skin and bone growth it is known as hypertrophic osteoarthropathy.

<span class="mw-page-title-main">Serpin</span> Superfamily of proteins with similar structures and diverse functions

Serpins are a superfamily of proteins with similar structures that were first identified for their protease inhibition activity and are found in all kingdoms of life. The acronym serpin was originally coined because the first serpins to be identified act on chymotrypsin-like serine proteases. They are notable for their unusual mechanism of action, in which they irreversibly inhibit their target protease by undergoing a large conformational change to disrupt the target's active site. This contrasts with the more common competitive mechanism for protease inhibitors that bind to and block access to the protease active site.

<span class="mw-page-title-main">Elastase</span> Enzyme

In molecular biology, elastase is an enzyme from the class of proteases (peptidases) that break down proteins. In particular, it is a serine protease.

<span class="mw-page-title-main">Liver disease</span> Medical condition

Liver disease, or hepatic disease, is any of many diseases of the liver. If long-lasting it is termed chronic liver disease. Although the diseases differ in detail, liver diseases often have features in common.

<span class="mw-page-title-main">Bronchoconstriction</span> Constriction of the terminal airways in the lungs

Bronchoconstriction is the constriction of the airways in the lungs due to the tightening of surrounding smooth muscle, with consequent coughing, wheezing, and shortness of breath.

<span class="mw-page-title-main">Respiratory disease</span> Disease of the respiratory system

Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bronchioles, alveoli, pleurae, pleural cavity, the nerves and muscles of respiration. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases such as bacterial pneumonia, pulmonary embolism, tuberculosis, acute asthma, lung cancer, and severe acute respiratory syndromes, such as COVID-19. Respiratory diseases can be classified in many different ways, including by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

Neonatal cholestasis refers to elevated levels of conjugated bilirubin identified in newborn infants within the first few months of life. Conjugated hyperbilirubinemia is clinically defined as >20% of total serum bilirubin or conjugated bilirubin concentration greater than 1.0 mg/dL regardless of total serum bilirubin concentration. The differential diagnosis for neonatal cholestasis can vary extensively. However, the underlying disease pathology is caused by improper transport and/or defects in excretion of bile from hepatocytes leading to an accumulation of conjugated bilirubin in the body. Generally, symptoms associated with neonatal cholestasis can vary based on the underlying cause of the disease. However, most infants affected will present with jaundice, scleral icterus, failure to thrive, acholic or pale stools, and dark urine.

<span class="mw-page-title-main">Alpha 1-antichymotrypsin</span> Protein-coding gene in the species Homo sapiens

Alpha 1-antichymotrypsin is an alpha globulin glycoprotein that is a member of the serpin superfamily. In humans, it is encoded by the SERPINA3 gene.

<span class="mw-page-title-main">Bronchitis</span> Inflammation of the large airways in the lungs

Bronchitis is inflammation of the bronchi in the lungs that causes coughing. Bronchitis usually begins as an infection in the nose, ears, throat, or sinuses. The infection then makes its way down to the bronchi. Symptoms include coughing up sputum, wheezing, shortness of breath, and chest pain. Bronchitis can be acute or chronic.

<span class="mw-page-title-main">Obstructive lung disease</span> Category of respiratory disease characterized by airway obstruction

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing (obstruction) of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling, and frequent medical clinic visits and hospitalizations. Types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms, and reversibility of airway obstruction. Cystic fibrosis is also sometimes included in obstructive pulmonary disease.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

Progressive disease or progressive illness is a disease or physical ailment whose course in most cases is the worsening, growth, or spread of the disease. This may happen until death, serious debility, or organ failure occurs. Some progressive diseases can be halted and reversed by treatment. Many can be slowed by medical therapy. Some cannot be altered by current treatments.

<span class="mw-page-title-main">Chronic obstructive pulmonary disease</span> Lung disease involving long-term poor airflow

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.

The Dutch hypothesis provides one of several biologically plausible explanations for the pathogenesis of chronic obstructive pulmonary disease (COPD), a progressive disease known to be aetiologically linked to environmental insults such as tobacco smoke.

<span class="mw-page-title-main">Emphysema</span> Medical condition

Emphysema is any air-filled enlargement in the body's tissues. Most commonly emphysema refers to the enlargement of air spaces (alveoli) in the lungs, and is also known as pulmonary emphysema.

Targeted lung denervation (TLD) is a procedure, that is currently being studied, to try to improve chronic obstructive pulmonary disease (COPD). Evidence to support its use is insufficient as of 2015. TLD is intended to block airway nerves of the parasympathetic nervous system to try to relax the airways. The procedure is done using a balloon catheter through a bronchoscope and uses radio frequency energy. The bronchoscope is passed through the person's mouth and into their lungs. A dual-cooled radiofrequency ablation catheter is passed through the bronchoscope to provide the treatment.

<span class="mw-page-title-main">John W. Walsh</span> American NGO leader and patient advocate, 1949–2017

John W. Walsh was an American non-profit leader and patient advocate. After being diagnosed with alpha-1 antitrypsin deficiency, he co-founded the Alpha-1 Foundation and AlphaNet, both of which serve people diagnosed with that condition, and the COPD Foundation, which serves people with chronic obstructive pulmonary disease. As an advocate for alpha-1 and COPD patients, Walsh lobbied before Congress for increased research funding and medical benefits for patients, and served on a number of health-related committees and organizations.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "alpha-1 antitrypsin deficiency". Genetics Home Reference. January 2013. Retrieved 12 December 2017.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Alpha-1 antitrypsin deficiency". GARD. 2016. Retrieved 12 December 2017.
  3. 1 2 Stradling, John; Stanton, Andrew; Rahman, Najib M.; Nickol, Annabel H.; Davies, Helen E. (2010). Oxford Case Histories in Respiratory Medicine. OUP Oxford. p. 129. ISBN   9780199556373.
  4. ↑ Clark, VC (May 2017). "Liver Transplantation in Alpha-1 Antitrypsin Deficiency". Clinics in Liver Disease. 21 (2): 355–365. doi:10.1016/j.cld.2016.12.008. PMID   28364818.
  5. 1 2 Marciniuk, DD; Hernandez, P; Balter, M; Bourbeau, J; Chapman, KR; Ford, GT; Lauzon, JL; Maltais, F; O'Donnell, DE; Goodridge, D; Strange, C; Cave, AJ; Curren, K; Muthuri, S; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working, Group (2012). "Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline". Canadian Respiratory Journal. 19 (2): 109–16. doi: 10.1155/2012/920918 . PMC   3373286 . PMID   22536580.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  6. ↑ Köhnlein, Thomas; Welte, T. (2007). Alpha-1 Antitrypsin Deficiency: Clinical Aspects and Management. UNI-MED Verlag AG. p. 16. ISBN   9781848151154.
  7. 1 2 Kumar V, Abbas AK, Fausto N, eds. (2005). Robbins and Cotran Pathological Basis of Disease (7th ed.). Elsevier/Saunders. pp. 911–2. ISBN   978-0-7216-0187-8.
  8. ↑ Vestbo J (2013). "Diagnosis and Assessment" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 9–17. Archived from the original (PDF) on 28 March 2016. Retrieved 9 August 2019.
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Patel, Dhiren; Teckman, Jeffrey H. (November 2018). "Alpha-1-Antitrypsin Deficiency Liver Disease". Clinics in Liver Disease. 22 (4): 643–655. doi:10.1016/j.cld.2018.06.010. PMID   30266154. S2CID   52883809.
  10. 1 2 3 Sandhaus, Robert A.; Turino, Gerard; Brantly, Mark L.; Campos, Michael; Cross, Carroll E.; Goodman, Kenneth; Hogarth, D. Kyle; Knight, Shandra L.; Stocks, James M. (2016). "The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult". Chronic Obstructive Pulmonary Diseases. 3 (3): 668–682. doi:10.15326/jcopdf.3.3.2015.0182. PMC   5556762 . PMID   28848891.
  11. 1 2 3 Silverman EK, Sandhaus RA (2009). "Alpha1-Antitrypsin Deficiency". New England Journal of Medicine. 360 (26): 2749–2757. doi:10.1056/NEJMcp0900449. PMID   19553648.
  12. ↑ Carlson, J.A.; Rogers, B.B.; Sifers, R.N. (1988). "Multiple tissues express alpha 1-antitrypsin in transgenic mice and man". J. Clin. Invest. 82 (1): 26–36. doi: 10.1172/JCI113580 . PMC   303472 . PMID   3260605.
  13. ↑ Ochieng, Pius; Nath, Sridesh; Macarulay, Reane (2018). "Phospholipid transfer protein and alpha-1 antitrypsin regulate Hck kinase activity during neutrophil degranulation". Nature. 8 (1): 15394. Bibcode:2018NatSR...815394O. doi:10.1038/s41598-018-33851-8. PMC   6193999 . PMID   30337619. S2CID   53017522.
  14. ↑ Barnes, Peter J. (2009). "Chapter 61 - Future Therapies". Asthma and COPD (second ed.). Basic Mechanisms and Clinical Management. pp. 737–749. doi:10.1016/B978-0-12-374001-4.00061-4. ISBN   9780123740014.
  15. ↑ Demkow, U; Overveld, FJ van (2010). "Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: Implications for treatment". Eur J Med Res. 15 (Suppl 2): 27–35. doi: 10.1186/2047-783x-15-s2-27 . PMC   4360323 . PMID   21147616.
  16. ↑ "Emphysema". Mayo Clinic. Mayo Foundation for Medical Education and Research (MFMER). Retrieved 16 November 2021.
  17. ↑ Donato, Leslie; Jenkins; et al. (2012). "Reference and Interpretive Ranges for α1-Antitrypsin Quantitation by Phenotype in Adult and Pediatric Populations". American Journal of Clinical Pathology. 138 (3): 398–405. doi: 10.1309/AJCPMEEJK32ACYFP . PMID   22912357 . Retrieved 17 January 2014.
  18. ↑ Townsend, S.A; Edgar, R.G; Ellis, P.R; Kantas, D; Newsome, P.N; Turner, A.M (2018). "Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease". Alimentary Pharmacology & Therapeutics. 47 (7): 877–885. doi: 10.1111/apt.14537 . PMID   29446109.
  19. ↑ "Chronic obstructive pulmonary disease in over 16s: diagnosis and management". www.nice.org.uk. National Institute for Health and Care Excellence. December 2018. Retrieved 11 August 2019.
  20. ↑ Gøtzsche, Peter C.; Johansen, Helle Krogh (20 September 2016). "Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease". The Cochrane Database of Systematic Reviews. 2016 (9): CD007851. doi:10.1002/14651858.CD007851.pub3. ISSN   1469-493X. PMC   6457738 . PMID   27644166.
  21. 1 2 3 Luisetti, M; Seersholm, N (February 2004). "Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency". Thorax. 59 (2): 164–9. doi:10.1136/thorax.2003.006494. PMC   1746939 . PMID   14760160.
  22. ↑ Sleisenger and Fordtran's Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management (Eleventh ed.). Philadelphia, PA: Elsevier. 29 June 2020. pp. 1189–1192. ISBN   978-0323609623.
  23. ↑ Laurell CB, Eriksson S (1963). "The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency". Scand J Clin Lab Invest. 15 (2): 132–140. doi:10.1080/00365516309051324.
  24. ↑ Sharp H, Bridges R, Krivit W, Freier E (1969). "Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder". J Lab Clin Med. 73 (6): 934–9. PMID   4182334.
  25. ↑ De Soyza, J; Pye, A; Turner, AM (December 2023). "Are clinical trials into emerging drugs for the treatment of alpha-1 antitrypsin deficiency providing promising results?". Expert Opinion on Emerging Drugs. 28 (4): 227–231. doi:10.1080/14728214.2023.2296088. PMID   38112023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.